col blocks we are bridge builder col blocks
COVID answers in Scientific Journals all over the world


13 Results       Page 1

 [1] 
SAGE Publications: Multiple Sclerosis Journal - Experimental Translational and Clinical
  original article Date Title Authors   All Authors
1 [GO] 2023―Apr―05 Preserved T cell but attenuated antibody response in MS patients on fingolimod and ocrelizumab following 2nd and 3rd SARS-CoV-2 mRNA vaccine Sarah Conway, Shrishti Saxena, Clare Baecher-Allan, Rajesh Krishnan, Maria Houtchens, Bonnie Glanz, et al. (+15)
2 [GO] 2022―May―23 Attitudes toward coronavirus disease 2019 vaccination in people with multiple sclerosis Ruth Ann Marrie, Casandra Dolovich, Gary R Cutter, Robert J. Fox, Amber Salter
3 [GO] 2022―May―04 Researching COVID-19 in progressive MS requires a globally coordinated, multi-disciplinary and multi-stakeholder approach-perspectives from the International Progressive MS Alliance Paola Zaratin, Brenda Banwell, Timothy Coetzee, Giancarlo Comi, Anthony Feinstein, Robert Hyde, et al. (+2)
4 [GO] 2022―Mar―22 Neutralizing antibody responses against SARS-CoV-2 in vaccinated people with multiple sclerosis Tirisham V. Gyang, John P. Evans, Joseph S. Miller, Kariss Alcorn, Juan Peng, Erica H. Bell, et al. (+4)
5 [GO] 2022―Mar―07 Perspectives and experiences with COVID-19 vaccines in people with MS John R. Ciotti, Dana C. Perantie, Brandon P. Moss, Kathryn C. Fitzgerald, Jeffrey A. Cohen, Ellen M. Mowry, et al. (+2)
6 [GO] 2021―Nov―29 Evaluation of short-term safety of COVID-19 vaccines in patients with multiple sclerosis from Latin America Ricardo Alonso, Aníbal Chertcoff, Felisa del V Leguizamón, Lorna Galleguillos Goiry, Maria B Eizaguirre, Roberto Rodríguez, et al. (+10)
7 [GO] 2021―Nov―29 Determining the best window for BNT162b2 mRNA vaccination for SARS-CoV-2 in patients with multiple sclerosis receiving anti-CD20 therapy Audrey Rico, Laetitia Ninove, Adil Maarouf, Clémence Boutiere, Pierre Durozard, Sarah Demortiere, et al. (+6)
8 [GO] 2021―Nov―26 Clinical features and outcomes of COVID-19 despite SARS-CoV-2 vaccination in people with multiple sclerosis Deja R Rose, Ahmad Z Mahadeen, Alise K Carlson, Sarah M Planchon, Jennifer Sedlak, Scott Husak, et al. (+3)
9 [GO] 2021―Aug―27 Research interrupted: The impact of the COVID-19 pandemic on multiple sclerosis research in the field of rehabilitation and quality of life Rebecca Maguire, Sinead Hynes, Barbara Seebacher, Valerie J Block, Kathy M Zackowski, Johanna Jonsdottir, et al. (+6)
10 [GO] 2021―May―31 COVID-19 vaccination willingness among people with multiple sclerosis Xinran M Xiang, Chris Hollen, Qian Yang, Barbara H Brumbach, Rebecca I Spain, Lindsey Wooliscroft
11 [GO] 2021―Feb―26 Expanded access to multiple sclerosis teleneurology care following the COVID-19 pandemic Marisa P McGinley, Shauna Gales, William Rowles, Zhini Wang, Wan-Yu Hsu, Lilyana Amezcua, Riley Bove
12 [GO] 2020―Oct―12 Natalizumab safety in paediatric-onset multiple sclerosis at the time of SARS-Cov-2 pandemic Monica Margoni, Paolo Gallo
13 [GO] 2020―Aug―11 Fatal COVID-19 in an MS patient on natalizumab: A case report Kathryn Rimmer, Rebecca Farber, Kiran Thakur, Genna Braverman, Dina Podolsky, Lauren Sutherland, et al. (+7)
 [1] 

13 Results       Page 1



[de][en]

Last change 2023―Oct―27 12:08:13 UTC

© Daten-Quadrat 2022       Done in 0.003 sec